Patent Number: 7,785,624

Title: Pharmaceutical latrunculin formulations

Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.

Inventors: Krishnamoorthy; Ramesh (Cary, NC), Trevino; Leo A. (Hurdle Mills, NC), Evans; Richard M. (Cary, NC), Evans, legal representative; Carole (Cary, NC)

Assignee: Inspire Pharmaceuticals, Inc.

International Classification: A61K 31/427 (20060101); A61K 9/20 (20060101)

Expiration Date: 8/31/12018